USA Flag An official website of the United States government
Official websites use .mil
A .mil website belongs to an official U.S. Department of War organization.
Secure .mil websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .mil website. Share sensitive information only on official, secure websites.
DEPARTMENT OF WAR - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

Vision – Improve treatments and find cures for people with ALS

Mission – Fund impactful research to develop ALS treatments

Amyotrophic Lateral Sclerosis Research Program Summary Sheet Cover Image
» Click on Image to View Program Summary Sheet

Amyotrophic Lateral Sclerosis Research Program Strategic Plan Cover Image
» Click on Image to View Strategic Plan

Amyotrophic Lateral Sclerosis (ALS), also known as "Lou Gehrig's disease," is a degenerative neurological disorder without a cure. For reasons that are not well understood, the nerve cells in the brain and spinal cord that control voluntary muscle movement gradually deteriorate. ALS can be difficult to diagnose because the initial symptoms are both subtle and vague and can be attributed to a number of other conditions. Average life expectancy after diagnosis ranges between 3 to 5 years from the onset of symptoms. It is estimated that 5-10% of all ALS cases are inherited (familial disease) while the remaining 90-95% are sporadic, with unknown etiology and risk factors. There is currently no known cure or therapy to effectively halt the progression of ALS. Evidence from scientific research suggests a mutually inclusive relationship between ALS and military service, with a higher rate of incidence in the Veteran population, without any known reason(s) for this incidence.

The ALSRP is guided by a vision to improve treatments and find cures for people with ALS. Through its award mechanisms and funding recommendations, the ALSRP specifically supports impactful research to develop ALS treatments.


ALSRP Initiatives



Congressional Appropriations Icon

Congressional Appropriations

  • $269.4 million FY07, FY09-24
  • $40 million
    FY25

Funding Summary Icon

Funding
Summary


Last updated Tuesday, January 6, 2026